摘要
Roxanna SADOUGHIFAR Prof
医学博士
Alopecia areta: New treatment approaches and overview of current therapies
Objectives: The objective of this discussion is to explore both current and emerging treatment approaches for alopecia areata, with a focus on evaluating the effectiveness and potential risks of each option. Emphasis will be placed on carefully selecting the most appropriate treatment based on the patient’s condition and preferences to optimize outcomes. Additionally, the latest consensus from European dermatologists will be discussed to provide insight into new advancements and guidelines in the field
Introduction: Alopecia areata is a chronic condition characterized by relapsing, nonscarring hair loss. Its clinical course can vary widely, with the possibility of spontaneous resolution, persistence, recurrence, or progression.. The unpredictability of alopecia areata, with its potential for recurrence or progression,causes emotional strain.Patients often experience uncertainty about the future, not knowing if or when their hair might grow back or fall out again. Managing alopecia areata requires a delicate personalized approach.
Materials / method: This abstract is based on my extensive clinical experience in treating Alopecia Areata using both classic and innovative approaches. I have integrated insights from the European Dermatologists Society (EADV) guidelines, which play a crucial role in shaping evidence-based treatments. Additionally, I have reviewed and incorporated findings from recently published breakthrough articles, reflecting the latest advancements in the field. The methodology includes a comparative analysis of traditional methods and novel therapies, focusing on efficacy, safety, and patient outcomes.
Conclusion: Treatment strategies depend on the severity of the condition and the extent of hair loss. Initial therapies often include intralesional and topical corticosteroids, as well as topical immunotherapy. Systemic treatments, such as oral baricitinib, ritlecitinib, and other Janus kinase (JAK) inhibitors, show promise in addressing more advanced cases. Additional therapies include excimer laser therapy, platelet-rich plasma (PRP), and photochemotherapy. Each option will be explored in detail in this lecture!
披露 - Roxanna SADOUGHIFAR
> 您是否获得了任何资金来支持您关于这个主题的研究?
不是
> 您在这项研究工作中是否获得过任何酬金、报酬或其他形式的补偿?
不是
> 您是否与任何可能与您研究中涉及的药物、材料或器械存在激烈竞争的实体有任何财务关系?
不是
> 您是否拥有或已申请过与您研究中所讨论的仪器、药物或材料相关的任何专利?
不是
这项工作没有任何直接或间接的资金支持。由作者自己承担责任。
Published on 2025年 4月 1日 - Recorded during IMCAS World Congress 2025